ProgenaBiome
Private Company
Funding information not available
Overview
Founded in 2017, ProgenaBiome is a private, physician-owned genetic research lab that bridges microbiome science and clinical application. Its core business involves providing microbiome testing services (the Flora Test) to physicians and patients while actively conducting research into the role of the gut microbiome in various diseases, including Parkinson's. The company's strategy centers on validating sequencing data for clinical use, developing its refloralization (FMT) protocols, and seeking collaborations with doctors, scientists, and pharmaceutical companies. It appears to be in an early-revenue stage, generating income from testing services while funding research initiatives.
Technology Platform
Genetic sequencing and bioinformatics platform for clinical microbiome analysis, used to inform diagnostic testing and personalized fecal microbiota transplantation (Refloralization™).
Opportunities
Risk Factors
Competitive Landscape
ProgenaBiome competes in the crowded microbiome testing market against companies like Viome, DayTwo, and uBiome (defunct). In the FMT/therapeutics space, it faces competition from larger biotechs (e.g., Seres Therapeutics, Finch Therapeutics) and non-profit stool banks. Its differentiation is its strong emphasis on clinical application and physician collaboration, but it lacks the reported funding of some venture-backed peers.